Mounjaro · Zepbound
Dual GIP/GLP-1 receptor agonist with superior weight loss outcomes vs semaglutide.
Tirzepatide is a dual GIP and GLP-1 receptor agonist. By activating both incretin pathways, it provides stronger appetite suppression and greater metabolic benefits than GLP-1 alone. Head-to-head SURMOUNT trials showed up to 22.5% body weight loss at the 15mg dose.
The following providers from our comparison carry this medication. Pricing and availability are verified May 2026.
Tirzepatide is a dual GIP and GLP-1 receptor agonist. By activating both pathways, it provides greater appetite suppression and metabolic benefits than GLP-1 alone. Clinical trials showed up to 22.5% body weight loss.
Mounjaro (for type 2 diabetes) and Zepbound (for weight management) are the FDA-approved brand-name tirzepatide products. Compounded tirzepatide is also available during FDA shortage periods.
Tirzepatide is a once-weekly subcutaneous injection. Dosing starts at 2.5mg and is titrated up to 15mg for diabetes (Mounjaro) or up to 15mg for weight management (Zepbound).
Find the right provider for Tirzepatide. Compare pricing, clinician quality, and shipping across all reviewed providers.
View full comparison →